Mechanisms of Parkinson’s disease-related proteins in mediating secondary brain damage after cerebral ischemia

TaeHee Kim1,2 and Raghu Vemuganti1,2,3,4

Abstract
Both Parkinson’s disease (PD) and stroke are debilitating conditions that result in neuronal death and loss of neurological functions. These two conditions predominantly affect aging populations with the deterioration of the quality of life for the patients themselves and a tremendous burden to families. While the neurodegeneration and symptomology of PD develop chronically over the years, post-stroke neuronal death and dysfunction develop rapidly in days. Despite the discrepancy in the pathophysiological time frame and severity, both conditions share common molecular mechanisms that include oxidative stress, mitochondrial dysfunction, inflammation, endoplasmic reticulum stress, and activation of various cell death pathways (apoptosis/necrosis/autophagy) that synergistically modulate the neuronal death. Emerging evidence indicates that several proteins associated with early-onset familial PD play critical roles in mediating the neuronal death. Importantly, mutations in the genes encoding Parkin, PTEN-induced putative kinase 1 and DJ-1 mediate autosomal recessive forms of PD, whereas mutations in the genes encoding leucine-rich repeat kinase 2 and α-synuclein are responsible for autosomal dominant PD. This review discusses the significance of these proteins with the emphasis on the role of α-synuclein in mediating post-ischemic brain damage.

Keywords
Parkinson's disease, cerebral ischemia, neurodegeneration, neuroprotection, α-synuclein

Introduction
Chronic neurodegenerative conditions that include Parkinson’s disease (PD), Alzheimer’s disease (AD) and Huntington’s disease (HD) show a progressive and irreversible loss of structure or function of neurons over time with devastating consequences that include a motor to cognitive dysfunction.1 Although the pathophysiologic mechanisms responsible for neurodegeneration in chronic disorders are not completely understood, there are many commonalities including oxidative stress, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, inflammation, autophagy, impairment of protein folding and abnormal post-translational modifications leading to overloading of the ubiquitin-proteasome system.2-5 Furthermore, several proteins were shown to be associated with the progression of these disorders, particularly those that form aggregates in the CNS over time.6,7 For instance, one of the pathological hallmarks of PD is the presence of Lewy Bodies, proteinaceous cytoplasmic inclusions mainly composed of aggregated α-synuclein (α-Syn).8 Similarly, AD is manifested by the accumulation of abnormally folded β-amyloid (Aβ) and hyperphosphorylated tau in the brain,9 and mutant and aggregated huntingtin proteins that disrupt retrograde transport in neurons play a pivotal role in the pathogenesis of HD.10,11 Neurodegeneration associated with acute conditions like stroke and traumatic brain injury (TBI) is also...
mediated synergistically by oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, and autophagy which play critical roles in its pathogenic progression.\(^\text{12-14}\) This similarity is surprising as the neuronal damage in chronic conditions like PD progresses over years, whereas acute conditions like stroke occur in a short span of hours to days. However, the intensity of mechanisms like oxidative stress, ER stress, and inflammation matches the time of progression as they are at a low, consistent level in chronic disorders, whereas they quickly go to a peak level and dissipate quickly in acute conditions.\(^\text{15-17}\) Interestingly, it was shown that silent strokes could lead to PD via inflammatory responses.\(^\text{18}\) In addition, there is a positive correlation of oligomeric form of PD-causing protein in the red blood cell between ischemic stroke and PD patients.\(^\text{19}\) Furthermore, several proteins involved in the pathogenesis of PD have been reported to play proteopathic roles under the ischemic condition. In this review, we discuss the significance of these proteins with an emphasis on the role of a\(^\text{-}\)Syn in promoting acute brain damage after stroke and the putative mechanisms of action.

**Clinical implications of PD and cerebral ischemia**

It has long been suggested that ischemic stroke is associated with PD. For instance, vascular Parkinsonism (VP), a form of atypical Parkinsonism, is produced by one or more small strokes, rather than by the gradual loss of nerve cells as seen in the more typical neurodegenerative PD.\(^\text{20}\) Furthermore, levodopa treatment is known to be less effective and vascular risk factors were more common in VP patients compared to typical PD patients.\(^\text{21}\) Supporting this phenomenon, a recent preclinical study revealed that silent striatal stroke induced by the middle cerebral artery occlusion in rodents, can cause PD and destroys dopaminergic neurons via inflammation in the substantia nigra.\(^\text{18}\) Postmortem studies further raised the possibility of the coexistence of PD and cerebrovascular disease and suggest that patients with Parkinsonism may have cerebrovascular disease without the distinct pathological hallmarks of PD.\(^\text{22,23}\) Earlier clinical studies also reported a higher incidence of ischemic stroke in PD patients compared to control subjects.\(^\text{24,25}\) In particular, the proportion of deaths due to vascular lesions of the brain is significantly higher in male PD patients 45–64 years of age compared with the general population.\(^\text{24}\) Despite such evidence, there is no direct evidence that PD-causing proteins are involved in the pathogenesis of clinical stroke cases. Although levels of oligomeric a\(^\text{-}\)Syn in the red blood cells of ischemic stroke patients were found to be positively correlated with that of PD patients,\(^\text{19}\) prospective studies are needed to clarify the role of PD proteins in human stroke cases.

**The proteopathic basis of neurodegenerative processes in PD and ischemic stroke**

PD is the second most common neurodegenerative disease after AD characterized primarily by the loss of dopaminergic neurons in the substantia nigra pars compacta leading to a striatal dopamine deficit. Symptoms of PD include bradykinesia, hypokinesia, rigidity, resting tremor, postural instability, sleep disturbances, depression and cognitive impairment, indicating a more widespread degenerative process.\(^\text{17}\) A pathological hallmark of sporadic PD is the presence of cytoplasmic proteinaceous inclusions called Lewy bodies, mainly composed of a\(^\text{-}\)Syn, ubiquitin, neurofilaments, and molecular chaperones.\(^\text{26}\) The role of Lewy bodies in the disease process and their status as a pathogenic marker of PD is still a matter of discussion. A breakthrough in PD research was the identification of genes which are responsible for monogenic familial forms. Although familial PD with specific genetic defects account for <10% of all cases of PD, the identification of these rare genes and their functions has provided tremendous insight into the pathogenesis of PD and opened up new areas of investigation. Mutations in the genes encoding Parkin, PINK1, and DJ-1 mediate autosomal recessive forms of PD and mutations in the genes encoding leucine-rich repeat kinase 2 (LRRK2) and a\(^\text{-}\)Syn are responsible for autosomal dominant PD. Sporadic and monogenic forms share important clinical, pathological, and biochemical features, notably the progressive demise of dopaminergic neurons in the substantia nigra. Therefore, insight into the function and dysfunction of PD-associated gene products can help elucidate the underlying mechanisms and new pathways in cell death.

Cerebral ischemia triggers a series of complex biochemical and molecular events that promote neuronal death and neurological dysfunction. These include, but not limited to, excitotoxicity, ionic imbalance, edema, oxidative stress, ER stress, and inflammation.\(^\text{14}\) These mechanisms promote necrosis as well as apoptosis and autophagy.\(^\text{27}\) Surprisingly all these mechanisms are also known to be central in promoting brain damage in chronic conditions like PD although the intensity and timing are different between the acute and chronic diseases. Furthermore, recent studies showed that the chronic neurodegeneration-related proteins including a\(^\text{-}\)Syn, DJ-1, Parkin and PINK1 are also involved in the neuronal death following acute insults like a stroke.
**α-Synuclein**

The structure of α-Syn. α-Syn is a small protein (14.5 kDa; 140 amino acid) abundantly expressed in the mammalian brain and localized primarily in presynaptic terminals. α-Syn has three structural domains: the amphipathic N-terminal region (residues 1 to 60), the central hydrophobic region (residues 61 to 95; also known as NAC; non-amyloid component) and the acidic C-terminal region (residues 96 to 140) (Figure 1). The N-terminal region is well conserved and binds to phospholipids to acquire an amphipathic α-helix structure.28 The central hydrophobic region enables α-Syn to form aggregates, rich in β-pleated sheets upon aggregation. The tertiary interactions between the three domains are known to stabilize and shield the NAC region from undergoing spontaneous oligimerization of α-Syn.29,30 At least five missense mutations in the N-terminal and several post-translational modifications including nitroxidation, phosphorylation, and ubiquitination in both the N- and C-terminals are implicated in the pathogenesis of PD and other synucleinopathies as they disrupt the intrinsic autoinhibitory mechanisms leading to oligomerization of α-Syn.31–35

**Oligomeric α-Syn and the cellular toxicity.** α-Syn aggregates, the major component of Lewy bodies, are implicated in the cytotoxicity and the pathogenesis of several neurodegenerative disorders.36–38 However, soluble oligomeric intermediates are considered as the major precipitators of PD pathology as mature fibrils are deemed benign precipitates by sequestration of toxic oligomers.39-41 Biochemical and genetic studies suggest that α-Syn directly interacts with a number of key players in the pathogenesis of synucleinopathies (Figure 2). α-Syn oligomers are thought to form annular structures and pore-like complexes in the lipid bilayer of the membranes resulting in disruption of calcium homeostasis.41–45 However, α-Syn oligomers were also thought to induce membrane permeabilization independent of pore-like complexes.46,47 α-Syn can also promote mitochondria-independent reactive oxygen species (ROS) production, by interacting with metal ions. In vitro studies showed that α-Syn has several binding sites for copper and the redox activities of α-Syn-Cu⁺ complexes can generate hydrogen peroxide.48,49 and these α-Syn-copper complexes are found to be neurotoxic and promote further oligomerization.50,51 The unfolded protein response (UPR) and the subsequent ER stress are neuroprotective in moderation. However, prolonged and/or excessive ER stress leads to neuronal death.52 In the brain of PD patients, expression of UPR activation markers, phospho-PERK and phospho-eIF2α, was observed to be increased and

---

**Figure 1.** The primary structure of α-Syn. α-Syn monomeric protein consists of an amphipathic N-terminal (amino acids 1–60; Red), a hydrophobic non-amyloid component (NAC; amino acids 61–95; Blue) and an acidic C-terminal (amino acids 96–140; Green). The N-terminal region is highly conserved between the synuclein family proteins and contains characteristic consensus apolipoprotein lipid-binding motifs (KTKEGV). This region adopts an amphipathic α-helical structure upon binding to negatively charged lipids, such as phospholipids present on cellular membranes. The central region is a hydrophobic zone that corresponds to the non-amyloid component and holds the amyloidogenic properties of the protein which allows α-Syn to undergo fibrillization, rich in β-structures. The C-terminal region is a negatively charged acidic segment rich in glutamic, aspartic, and proline residues which hosts several post-translational modification sites including S129. Five missense mutations identified to date (purple) as well as the S129 phosphorylation site (blue) are marked with arrowheads. KTKEGV repeat motifs within the N-terminal are shown in bold. Amino acids associated with nitroxidative modifications (methionine, tyrosine, and histidine) present in either the N-terminal or the C-terminal region are underscored.
colocalized with α-Syn. An in vivo study further showed that toxic α-Syn oligomers accumulate within ER lumen and α-Syn oligomer-dependent ER stress can be rescued by treatment with Salubrinal, which inhibits eIF2α and thus decreases protein overload. α-Syn oligomers are also shown to promote inflammatory responses and autophagy.

**α-Syn and mitochondrial dysfunction.** Mitochondrial homeostasis are dependent on fusion and fission dynamics, and their perturbation results in mitochondrial dysfunction which is implicated in neurodegenerative disorders. In the brains of PD patients, aggregated α-Syn was observed to be localized in the inner mitochondrial membranes where it interacts with complex I resulting in the reduced mitochondrial complex I activity and increased ROS production. α-Syn aggregates also interact with other mitochondrial proteins such as carbonic anhydrase, enolase, and lactate dehydrogenase which were found to be oxidized in brains of transgenic mice overexpressing mutant A30P α-Syn. α-Syn overexpression was shown to significantly increase the translocation of mitochondrial fission protein Drp1 via extracellular signal-regulated kinase (ERK) pathway and induced mitochondrial cytochrome C release and caspase-9 and -3 activities promoting apoptosis. In contrast, inhibition of α-Syn expression prevented MPP+ induced mitochondrial fragmentation in vitro. As mitochondrial dysfunction is thought to be a key player in...
neurodegeneration, these studies suggest that α-Syn could potentially play a pathogenic role in a broad spectrum of neurodegenerative diseases.

**α-Syn and post-translational modifications.** As discussed above, post-translational modifications are known to impact the pathological role of α-Syn including its aggregation, fibrillation, Lewy body formation and neurotoxicity. Of various post-translational modifications α-Syn can undergo, serine-129 (S129) phosphorylation is considered as a defining hallmark of PD and other synucleinopathies. In the post-mortem PD patient brains, >90% of the α-Syn aggregates are known to be S129 phosphorylated, but its functional significance is not yet completely elucidated. Many kinases can promote S129 phosphorylation of α-Syn, and overexpression of GRK2 and GRK6 in Drosophila and rodent PD models showed enhanced and accelerated neuronal death. In contrast, overexpression of Polo-like kinase 2 (PLK2) which also mediates α-Syn S129 phosphorylation was shown to reduce α-Syn-associated dopaminergic neuronal loss and ameliorate hemiparkinsonian motor impairment presumably by enhancing autophagy in adult rodents. Although further studies are required for elucidating the exact function of S129 phosphorylation on α-Syn toxicity, these studies emphasize the significance of the kinase responsible for the phosphorylation rather than the phosphorylation itself.

**α-Syn: Unanswered questions.** Although extensive research over the last two decades has provided tremendous insight into the role of α-Syn in the pathogenesis of PD, there are still many unanswered questions that need to be addressed for developing therapies targeting α-Syn. While the predominant view is that α-Syn exists as an unfolded monomer under native conditions, recent studies showed that α-Syn may exist as a helically folded tetramer that resists aggregation and fibrillation in the normal brain. Neurons derived from PD patients expressing A53T mutant α-Syn contained decreased tetramers. In vitro studies further showed that α-Syn missense mutations (A30P, E46K, and A53T) lower α-Syn tetramer: monomer ratio and induce neurotoxicity and round inclusions. In addition, mutagenesis studies revealed that the α-Syn KTKEGV repeat motifs present in the N-terminus mediate physiological tetramerization and perturbing them causes PD-like neurotoxicity. Despite these studies, it is not convincingly established if α-Syn exists as a monomer or a tetramer under normal conditions.

Another enigma regarding α-Syn pathology is the mechanisms that modulate α-Syn expression during pathological states. Interestingly, microRNAs miRNA-7 and miRNA-153 were shown to synergistically target α-Syn mRNA to repress its protein expression. In human embryonic kidney cells (HEK293T) challenged with hydrogen peroxide, premiR-7 transfection decreased α-Syn protein expression and cell death. In addition to direct effects of miRNAs on the α-Syn protein expression, these small non-coding RNAs may also have indirect implications for the α-Syn pathology in a specific cell type. For example, miR-155 knockout mice showed reduced microgliosis and neuroprotection despite α-Syn overexpression. miR-155 was also observed to be essential for α-Syn-induced major histocompatibility complex class II (MHCII) and inducible nitric oxide synthase (iNOS) expression in microglia. Although further studies are needed, these findings not only provide mechanisms by which α-Syn levels are regulated in disease brains but also raise the possibility that miRNA based therapy is feasible for α-Synucleinopathies.

**α-synuclein and stroke.** Interestingly, cellular environment following cerebral ischemia that includes inflammation, oxidative stress and ER stress potentially provides optimal conditions for α-Syn aggregation. In PD and other chronic neurodegenerative conditions, α-Syn aggregates exacerbate cellular toxicity by interacting with lipid membranes, metal ions, ER, mitochondria. Stroke can also either initiate or accelerate progressive neurodegenerative processes and is a known epidemiologic risk factor for AD. Significance of α-Syn in modulating ischemic brain injury was demonstrated by multiple labs (Table 1). Ishimaru et al. and Polymeropoulos et al. showed that a brief global ischemia in gerbils resulted in increased α-Syn (aka precursor protein of non-Aβ component of AD amyloid; NACP) immunoreactivity in the hippocampus where neurons died and proposed that NACP may be related to several neurodegenerative conditions. Subsequently, Hu et al. showed that hypoxia/ischemia increases α-Syn protein levels in the rat cerebral cortex, and Yoon et al. reported increased α-Syn immunoreactivity and protein levels in the hippocampal CA1 region following global ischemia in gerbils and this process was more prominent in aged than young animals. More importantly, increased α-Syn expression and neuronal death were attenuated by treatment with the antioxidant enzyme SOD1, indicating that ROS promotes α-Syn expression and aggregation. Furthermore, global cerebral ischemia in α-Syn knockout mice resulted in increased prostaglandin levels indicating the role of α-Syn in mediating post-ischemic inflammatory responses. This study suggested that α-Syn induction after ischemia may be neuroprotective by reducing the post-ischemic brain prostaglandin formation, but later studies challenged this notion. Although prostaglandin is implicated in
Table 1. Role of α-Syn in cerebral ischemia.

| Model               | Duration | Age/Sex | Species | Expression | Observations | Ref. |
|---------------------|----------|---------|---------|------------|--------------|------|
| Global ischemia     | 5 min    | YA; M   | Gerbil  | upregulated| ↑ α-Syn around blood vessels in CA1 on day 4; ↑ α-Syn† tubal structures on month 6 | 84   |
| HI                  | 90 min   | P7; F   | Rat     | upregulated| 2-fold increase 2 h after HI | 86   |
| Global ischemia     | 5 min    | 6 m, 24 m; M | Gerbil | upregulated| ↑ α-Syn in CA1 in aged gerbil; SOD1 inhibited α-Syn | 87   |
| Global ischemia     | 30 sec   | 9–11 m; M | Mouse   | N/A        | α-Syn+/− increased brain PG formation following ischemia | 88   |
| tMCAO               | 30 min   | 8w; M   | Mouse   | upregulated| Brief ischemia induced α-Syn aggregation, worsened damage | 91   |
| tMCAO               | 60–90 min| YA; M   | Rat, Mouse | upregulated| ↓ α-Syn reduced infarcts and improved neurological recovery | 92   |

YA: young adults; M: male; F: female; P: postnatal; m: months; w: weeks; HI: hypoxia/ischemia; tMCAO: transient middle cerebral artery occlusion; PG: prostaglandin; ↑: increase; ↓: decrease.

Both pro-inflammatory and anti-inflammatory responses in different biologic systems, a recent in vivo study showed that stimulation of prostaglandin D2 receptor DP1 is neuroprotective in the rodent ischemic brain. Furthermore, Unal-Cevik et al. reported that a brief ischemic insult is sufficient to induce α-Syn aggregation in neurons in adult mice. When subjected to a brief ischemia, α-Syn overexpressing transgenic mice showed exacerbated infarction and enhanced 3-nitrotyrosine immunoreactivity, indicating oxidative/nitrative stress as a potential mechanism of α-Syn-mediated toxicity similar to what was shown in PD. Recent studies from our laboratory also conclusively demonstrated that α-Syn induced after transient focal ischemia plays a detrimental role. We observed that transient focal ischemia induced by MCAO in adult rats significantly upregulates α-Syn mRNA and protein levels, and knockdown of α-Syn decreases infarction and promotes better neurobehavioral recovery. Knockdown of α-Syn also attenuated known ischemic pathological markers including mitochondrial dysfunction (Drp1), apoptosis (cleaved caspase-3), autophagy (LC-3 II/I ratio) as well as oxidative stress (3-nitrotyrosine). In addition, we observed that α-Syn protein oligomerizes, aggregates, and translocates to neuronal nuclei in both rat and human post-stroke brain. α-Syn knockout mice showed curtailed mortality, smaller infarcts, and better neurological recovery when subjected to transient focal ischemia. Furthermore, we observed that phosphorylation of α-Syn is responsible for its toxicity in the post-stroke brain as mice that lack PLK2 (the predominant kinase that mediates S129 phosphorylation of α-Syn) showed better functional recovery and smaller infarct after transient focal ischemia. These studies show that α-Syn plays a critical role even in the pathogenesis of ischemic stroke. Prospective studies will elucidate the exact mechanisms of α-Syn-mediated ischemic cell death.

Parkin

Parkin is a widely expressed cytosolic ubiquitin E3 ligase in the brain that mediates mono- and polyubiquitination of many proteins to regulate a variety of cellular processes. A number of proteins identified as Parkin substrates are implicated in the pathogenesis of PD. Among those, Parkin-mediated degradation of the GTPase cell division control-related protein-1 (CDCrel-1), is known to induce dopaminergic neurodegeneration in the rodent brain. In addition, overexpression of Parkin-associated endothelin receptor-like receptor (Pael-R) induces the unfolded stress response in dopaminergic neurons, and Parkin attenuates insoluble Pael-R-mediated cellular toxicity presumably through ubiquitination. Furthermore, the α-Syn-interacting protein, synphilin-1, interacts with and is polyubiquitinated by Parkin leading to the formation of protein aggregates when overexpressed together with α-Syn. Recent studies suggest that lysine-63-mediated ubiquitination on synphilin-1 may participate in the degradation of Lewy body inclusion independent of the UPS, implicating its role in the inclusion formation. Overall, the catalytic activities of Parkin were shown to be neuroprotective and counters diverse cellular insults including α-Syn toxicity and UPS dysfunction, accumulation of Pael-R (a substrate of Parkin), and kainite-induced excitotoxicity.

Parkin gene is a common cause of monogenic PD, and Parkin can undergo >100 types of mutations including exonic rearrangements, point mutations, and small deletions or insertions. Furthermore, Parkin can be inactivated by post-translational
modifications due to oxidative and nitrosative stress as seen in sporadic PD.\textsuperscript{101,102} Parkin inactivation leads to accumulation of Parkin substrates like aminocytanyl-tRNA synthetase-interacting multifunctional protein type 2 (AIMP2) and far upstream element-binding protein 1 (FBP1) which leads to neurodegeneration in PD.\textsuperscript{103,104} The nonreceptor tyrosine kinase c-Abl phosphorylates tyr-143 and thus inhibits ubiquitin E3 ligase activity of Parkin leading to neuronal degeneration in rodent MPTP model.\textsuperscript{105} Concomitantly, activated c-Abl further contributes to \textalpha-Syn-induced neurodegeneration in the rodent brain.\textsuperscript{106} Parkin inactivation also leads to induction of its substrates PARIS (ZNF746) and RTP801/REDD1, which promote dopaminergic neurodegeneration. Once accumulated, PARIS represses the peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1\textalpha) and its downstream neuroprotective target gene NRF-1,\textsuperscript{107} while RTP801/REDD1 is a negative regulator of survival kinases mTOR and Akt and hence promotes apoptosis.\textsuperscript{108} Taken together, these studies indicate that Parkin is an essential neuroprotective protein, and its inactivation promotes neurodegeneration.

### PINK1

PTEN-induced kinase 1 (PINK1) is a mitochondrial serine-threonine kinase that is ubiquitously expressed throughout the brain and is found in most cell types.\textsuperscript{109} More than 40 mutations in PINK1 gene are known to promote autosomal recessive PD.\textsuperscript{110,111} Several lines of evidence indicate that PINK1 is also a neuroprotective protein. An early study showed that wild-type, but not mutant PINK1 protects SH-SY5Y cells against stress-induced mitochondrial dysfunction and apoptotic cell death.\textsuperscript{42} Depletion of PINK1 both in vitro and in vivo was shown to exacerbate \textalpha-Syn aggregation-mediated toxicity as well as promote proteasomal inhibition.\textsuperscript{112,113} In contrast, reinstating PINK1 in Drosophila can rescue \textalpha-Syn-induced pathologic phenotypes although the mechanisms of how PINK1 mitigating \textalpha-Syn toxicity are not clearly known.\textsuperscript{114} PINK1 colocalizes and phosphorylates TRAP1 (TNF receptor-associated protein 1; HSP75), which is a protein chaperone that protects mitochondria from oxidative stress.\textsuperscript{115} In Drosophila, TRAP1 overexpression was shown to rescue PINK1 loss-of-function phenotypes.\textsuperscript{116}

Much attention is given to the role of PINK1 in conjunction with Parkin in promoting the clearance of impaired mitochondria. Termined mitophagy, it is the highly selective autophagy-based process representing a critical mechanism to eliminate damaged and dysfunctional mitochondria, thus protecting cells from aging, oxidative stress, and even apoptotic cell death.\textsuperscript{117} When mitochondria are damaged, mitochondrial membrane depolarization leads to PINK1 accumulation on the outer membrane, which recruits Parkin from cytosol that ubiquitinates mitofusin 1, mitofusin 2 and P62/SQSTM1 that promotes mitophagy to recycle the healthy mitochondrial components.\textsuperscript{117-124} A recent study suggested that PINK1 can also promote mitophagy without involving Parkin by directly phosphorylating autophagy receptors NDP52 and optineurin which in turn recruit the autophagy factors ULK1, DFCP1, WIPI1 as well as LC3.\textsuperscript{125} This evidence indicates that PINK1 and Parkin, the two genes implicated in the autosomal recessive PD, work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in PD.

Similar to their role in PD and other neurodegenerative disorders, even after stroke, Parkin and PINK1 are thought to regulate the mitochondrial integrity and thereby protect neurons from stress-induced mitochondrial dysfunction.\textsuperscript{126-128} Transient focal ischemia in adult mice was shown to markedly downregulate Parkin protein expression within the first 24 h of reperfusion.\textsuperscript{129} Overexpression of Parkin in primary cortical neurons further showed that neurons were protected from injury induced by ER stress which is a known mediator of post-ischemic secondary brain damage.\textsuperscript{129} On the contrary, treatment of mice subjected to transient focal ischemia with ER stress inducers tunicamycin and thapsigargin prevented post-ischemic Parkin depletion leading to its translocation to mitochondria and activation of mitophagy.\textsuperscript{130,131} In addition, the neuroprotective effects of these ER stress inducers were reversed by Parkin knockdown and/or knockout.\textsuperscript{130,131} Surprisingly, recent studies showed that Parkin and PINK1 were upregulated in cortical penumbra following photothrombotic focal ischemia in rats and promote the survival of penumbral neurons.\textsuperscript{132,133} Moreover, Parkin protein upregulation was also shown in the rat brain after transient focal cerebral ischemia induced by MCAO.\textsuperscript{134} Thus, it is still premature to conclude the definitive role of Parkin in ischemic brain damage.

### DJ-1

DJ-1 is a small ubiquitously expressed protein in the brain that exists as a homodimer in cytoplasm, mitochondria, and nucleus.\textsuperscript{135-137} DJ-1 is an oxidative stress response protein that defends cells against ROS.\textsuperscript{138-140} DJ-1 is thought to help maintain the integrity of mitochondria, presumably by interacting with complex I, and thereby minimizing the production of mitochondria-dependent oxidative stress leading to cytoprotection.\textsuperscript{141} Loss of DJ-1 leads to pathological mitochondrial phenotypes including reduced...
membrane potential, increased fragmentation, and accumulation of autophagic markers. Studies showed that brains of AD and PD patients contain high levels of oxidized DJ-1 which is thought to be neuroprotective. The neuroprotective potential of DJ-1 is considered to be due to post-translational modifications including oxidation of cysteine C106, SUMOylation of lysine K130 and transnitrosylation of cysteine residues C46, C53, and C106. Especially, from the transnitrosylated C106 residue, the NO group can be transferred to phosphatase and tensin homolog (PTEN) that decreases its phosphatase activity leading to neuronal survival. Although DJ-1 directly quenches some ROS via oxidation of Cysteine residues, this effect is not deemed a major contributor to the protective function of DJ-1. The neuroprotective activity of DJ-1 is thought to be multifactorial that includes chaperoning misfolded proteins including α-Syn and controlling its aggregation, activating SOD1 and modulating transcriptional regulators like p53, nuclear factor erythroid 2-related factor 2 (Nrf2) and protein-associated splicing factor (PSF) as well as by acting as a cysteine protease. DJ-1 acts in parallel with PINK1/Parkin to protect mitochondria during oxidative stress. Overexpression of Parkin or PINK1 prevents rotenone-induced mitochondrial fragmentation in the absence of DJ-1 in human dopaminergic cells. On the contrary, DJ-1 overexpression ameliorates PINK1, but not Parkin mutant-mediated mitochondrial dysfunction in Drosophila. Furthermore, mitochondrial fragmentation induced by α-syn overexpression in C. Elegans was shown to be mitigated by coexpression of wild-type PINK1, Parkin or DJ-1 with α-Syn but not by mutant forms of PINK1, Parkin or DJ-1.

DJ-1 is the most studied PD-causing protein in ischemic stroke setting due to its known neuroprotective roles in PD and other neurodegenerative conditions as an antioxidant as well as redox-sensitive molecular chaperone. Consistent with previous findings in PD, several studies showed that focal ischemia in rodents induces DJ-1 protein expression which prevents ischemic neuronal death by suppressing ROS production and acting as a redox-sensitive molecular chaperone. Biochemical and immunocytochemical studies revealed that when rat primary neuronal cultures were subjected to oxygen-glucose deprivation, DJ-1 translocates to mitochondria and nucleus which was thought to protect the cells. Interestingly, the translocated mitochondrial DJ-1 was subsequently observed to be secreted into the medium which is an essential step in DJ-1-mediated neuroprotection. In vivo and in vitro studies also showed the significance of astrocytic DJ-1 in response to post-ischemic oxidative stress. Following focal ischemia, activated astrocytes induced DJ-1 expression in the rat brain. Furthermore, when primary astrocytic cells were treated with H2O2, DJ-1 was observed to be secreted from astrocytes and scavenged hydroxyl radicals. However, the functional significance DJ-1 secretion is not clear yet.

Judging from previous evidence from PD and other neurodegeneration models, α-Syn aggregates might prevent the neuroprotective potential of DJ-1 after ischemia. Brain tissue from PD patients was shown to contain large molecular complexes (>2000 kDa) of α-Syn and DJ-1. In addition, decreased DJ-1 solubility was observed in the brains of PD patients. These studies suggest that α-Syn aggregates recruit DJ-1 to form insoluble inclusions and thereby attenuate its antioxidant neuroprotective ability. DJ-1 may also exert cellular protection by regulating transcription factors involved in the cell death. In support to this notion, DJ-1 was shown to negatively regulate p53 in response to oxidative stress. In zebrafish model of PD, DJ-1 deficiency resulted in increased p53 and Bax (apoptosis regulator) expression when challenged by H2O2. Activation of p53 is also involved in apoptotic cell death in cerebral ischemia and in vivo administration of p53 inhibitor pifithrin-α induced neuroprotection in rats subjected to focal ischemia. Taken together, it could be hypothesized that ischemic stress-induced α-Syn accumulation contributes, at least in part, to the increased p53 levels via suppressing DJ-1 solubility.

LRRK2

Leucine-rich repeat kinase 2 (LRRK2) is a multidomain protein (280 kDa, 2527 amino acid) which contains a central catalytic core that includes a Ras of complex (ROC), a GTPase protein domain, a carboxy-terminal of Roc (COR) domain and a kinase domain. The central catalytic core is surrounded by several potential protein–protein interacting domains including leucine-rich repeats and the WD40 domain. Mutations in the LRRK2 (R1441C, R1441G, and R1441H in the ROC domain, G2019S and I2020T in the kinase domain and Y1699C in the COR domain) are thought to be responsible for both familial and sporadic PD. Although the exact functional consequences of various LRRK2 mutations are not known, mutations in the ROC and COR domains decrease GTPase activity while mutations in the kinase domain increases kinase activity. Among the known LRRK2 mutations, G2019S mutation in the kinase domain shows the most prevalence in PD population. As G2019S mutation is the most prevalent in the PD population, increased LRRK2 kinase activity by G2019S mutation implicates significance in the pathogenesis of monogenic PD. In addition,
polymorphism within the LRRK2 gene is also correlated with sporadic PD risk. Many studies further showed that LRRK2 variants that include A419V, R1628P, and G2385R mutations increase risk for sporadic PD in Asians. Interestingly, there might be an association between LRRK2 and other PD genes; and many PD patients with LRRK2 mutations exhibit α-Syn-positive Lewy bodies and tau-related pathology.

LRRK2 is known to phosphorylate Tau directly or indirectly by activating GSK-3β which is a predominant Tau kinase. Tau is a microtubule-associated protein that is predominantly expressed in CNS and regulates neurite outgrowth and axonal transport by modulating tubulin assembly and microtubule stability. Hence, proper functioning of Tau is essential for neuronal plasticity and memory consolidation. The microtubule-binding ability of Tau is regulated by several post-translational modifications. Particularly, hyperphosphorylation of Tau promotes neuronal degeneration, and the fibrillar deposits of highly phosphorylated Tau is a defining marker of neurodegeneration including. Studies in PD and AD models showed co-localization of α-Syn with phospho-GSK-3β and phospho-Tau, and indicated that α-Syn may act as a scaffolding molecule that is necessary for the activation of GSK-3β and the subsequent Tau hyperphosphorylation. Taken together, these studies indicate that LRRK2 may be critically involved in the Tau pathology in PD.

As indicated above, LRRK2 activates GSK-3β by phosphorylation leading to tau hyperphosphorylation in PD. In parallel to this, cerebral ischemia in rodents was shown to increase GSK-3β-mediated tau hyperphosphorylation that colocalizes with TUNEL staining implicating its role in apoptotic cell death. Concomitantly, GSK-3β downregulates Nrf2 following cerebral ischemia, which is known
to reduce levels of hyperphosphorylated tau protein by inducing autophagy adaptor protein NDP52. Furthermore, α-Syn was shown to be induced following cerebral ischemia and its knockdown decreases post-ischemic mitochondrial fragmentation and apoptosis.92 Thus, LRRK2 might contribute to post-ischemic apoptotic cell death as well by modulating tau phosphorylation in the presence of α-Syn (Figure 4). Future studies will show the functional significance of LRRK2 to post-stroke brain damage.

**Conclusions**

The pathophysiologic mechanisms of neuronal death and therapeutic development for chronic neurodegenerative diseases like PD and acute injuries like stroke are usually investigated separately. However, many molecular mechanisms that promote secondary brain injury like inflammation, oxidative stress, ER stress, apoptosis, and autophagy can be seen in both chronic and acute CNS insults although their intensity and timing are different. Furthermore, observations like aggregation of α-Syn and depletion of proteins like DJ-1, PINK1, and Parkin after cerebral ischemia suggest that the mechanisms that are known to promote pathology in chronic conditions might also contribute to neuronal death after stroke. However, the causal relationship between the chronic neurodegeneration-associated proteins and cell death in stroke remains to be established beyond doubt. It is possible that neuronal cell injury may be caused by a direct toxic effect of protein aggregates or protein depletion. Conversely, abnormal protein levels could arise due to the pathological cellular environment created by injured neurons. Future studies are warranted to elucidate the molecular mechanisms underlying pathological processes mediated by mutual key proteins.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported, in part, by the U.S. Department of Veterans Affairs Merit Review Grant (I01 BX002985) and National Institute of Health Grants. TaeHee Kim was supported by the American Heart Association (15IRG23050015). Figures were created using the Servier Medical Art image bank with appropriate modifications.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**References**

1. Sheikh S, Safia, Haque E, et al. Neurodegenerative diseases: Multifactorial conformational diseases and their therapeutic interventions. *J Neurodegener Dis* 2013; 2013: 563481.
2. Nixon RA. The role of autophagy in neurodegenerative disease. *Nat Med* 2013; 19: 983–997.
3. Barnham KJ, Masters CL and Bush AI. Neurodegenerative diseases and oxidative stress. *Nat Rev Drug Discov* 2004; 3: 205–214.
4. Petrucelli L and Dawson TM. Mechanism of neurodegenerative disease: Role of the ubiquitin proteasome system. *Ann Med* 2004; 36: 315–320.
5. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. *Biochim Biophys Acta* 1998; 1366: 211–223.
6. Takalo M, Salminen A, Soininen H, et al. Protein aggregation and degradation mechanisms in neurodegenerative diseases. *Am J Neurodegener Dis* 2013; 2: 1–14.
7. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. *Nat Rev Neurosci* 2003; 4: 49–60.
8. Kim WS, Kagedal K and Halliday GM. Alpha-synuclein biology in Lewy body diseases. *Alzheimers Res Ther* 2014; 6: 73.
9. Bloom GS. Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurol* 2014; 71: 505–508.
29. Bertoncini CW, Jung YS, Fernandez CO, et al. Release of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A 2005; 102: 1430–1435.
30. Dedmon MM, Lindorff-Larsen K, Christodoulou J, et al. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc 2005; 127: 476–477.
31. Heijajaoui M, Butterfield S, Fauvet B, et al. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: Alpha-synuclein phosphorylation at tyrosine 125. J Am Chem Soc 2012; 134: 5196–5210.
32. Li J, Uversky VN and Fink AL. Effect of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 2001; 40: 11604–11613.
33. Chavarria C and Souza JM. Oxidation and nitrification of alpha-synuclein and their implications in neurodegenerative diseases. Arch Biochem Biophys 2013; 533: 25–32.
34. Proukakis C, Dudzik CG, Brier T, et al. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 2013; 80: 1062–1064.
35. Lesage S, Anheim M, Lotournel F, et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73: 459–471.
36. Kowall NW, Hantrye P, Brouillet E, et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000; 11: 211–213.
37. Narhi L, Wood SJ, Steavenson S, et al. Both familial Parkinson’s disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999; 274: 9843–9846.
38. Conway KA, Harper JD and Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4: 1318–1320.
39. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011; 108: 4194–4199.
40. Outeiro TF, Putcha P, Tetzlaff JE, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008; 3: e1867.
41. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007; 27: 9220–9232.
42. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 2004; 30467: 1158–1160.
43. Ding TT, Lee SJ, Rochet JC, et al. Annular alpha-synuclein protofilibrils are produced when spherical protofilibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002; 41: 10209–10217.
44. Volles MJ, Lee SJ, Rochet JC, et al. Vesicle permeabilization by protofilibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry 2001; 40: 7812–7819.
45. Lashuel HA and Lansbury PT Jr. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 2006; 39: 167–201.
46. Stefanovic AN, Stockl MT, Claessens MM, et al. alpha-Synuclein oligomers distinctively permeabilize complex model membranes. FEBS J 2014; 281: 2838–2850.
47. van Rooijen BD, Claessens MM and Subramanian V. Membrane permeabilization by oligomeric alpha-synuclein: In search of the mechanism. PLoS One 2010; 5: e14292.
48. Wang C, Liu L, Zhang L, et al. Redox reactions of the alpha-synuclein-Cu(+) complex and their effects on neuronal cell viability. Biochemistry 2010; 49: 8134–8142.
49. Binolfi A, Lamberto GR, Duran R, et al. Site-specific interactions of Cu(II) with alpha and beta-synuclein: Bridging the molecular gap between metal binding and aggregation. J Am Chem Soc 2008; 130: 11801–11812.
50. Wang X, Moualla D, Wright JA, et al. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J Neurochem 2011; 113: 704–714.
51. Wright JA, Wang X and Brown DR. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J 2009; 23: 2384–2393.
52. Lindholm D, Wootz H and Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ 2006; 13: 385–392.
53. Hoozemans JJ, van Haastert ES, Eikelenboom P, et al. Activation of the unfolded protein response in Parkinson’s disease. Biochem Biophys Res Commun 2007; 354: 707–711.
54. Colla E, Jensen PH, Pletnikova O, et al. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 2012; 32: 3301–3305.
55. Smith WW, Jiang H, Pei Z, et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 2005; 14: 3801–3811.
56. Fellner L, Irschick R, Schanda K, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013; 61: 349–360.
57. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson’s disease. FASEB J 2005; 19: 533–542.
58. Colasanti T, Vomero M, Alessandri C, et al. Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes. Cell Death Dis 2014; 5: e1265.
59. Lee HJ, Khoshaghideh F, Patel S, et al. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004; 24: 1888–1896.
60. Chen H and Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy—in neurodegenerative diseases. Hum Mol Genet 2009; 18: R169–R176.
61. Reeves AK, Ludtmann MH, Angelova PR, et al. Aggregated alpha-synuclein and complex I deficiency: Exploration of their relationship in differentiated neurons. Cell Death Dis 2015; 6: e1820.
62. Chinta SJ, Mallajosyula JK, Rane A, et al. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 2010; 486: 235–239.
63. Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283: 9089–9100.
64. Poon HF, Frasier M, Shreve N, et al. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice – A model of familial Parkinson’s disease. Neurobiol Dis 2005; 18: 492–498.
65. Gui YX, Wang XY, Kang WY, et al. Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1. Neurobiol Aging 2012; 33: 2841–2854.
66. Tanaka Y, Engeler S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001; 10: 919–926.
67. Zhu M, Li W and Lu C. Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines. PLoS One 2012; 7: e36377.
68. Schmid AW, Fauvet B, Moniatte M, et al. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics 2013; 12: 3543–3558.
69. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson’s disease. J Neurol 2003; (250 Suppl 3): III11–14.
70. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160–164.
71. Chen L and Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005; 8: 657–663.
72. Sato H, Arawaka S, Hara S, et al. Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease. J Neurosci 2011; 31: 16884–16894.
73. Oueslati A, Schneider BL, Aebischer P, et al. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A 2013; 110: E3945–E3954.
74. Wang W, Perovic I, Chittuluru J, et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 2011; 108: 17797–1802.
75. Bartels T, Choi JG and Selkoe DJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107–110.
76. Dettmer U, Newman AJ, Soldner F, et al. Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 2015; 6: 7314.
alpha-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. Proc Natl Acad Sci U S A 2015; 112: 9596–9601.
78. Burre J, Vivona S, Diao J, et al. Properties of native brain alpha-synuclein. Nature 2013; 49845: E4-6; discussion E6-7.
79. Fauvet B, Mbefo MK, Fares MB, et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 2012; 287: 15345–15364.
80. Duxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 2010; 285: 12726–12734.
81. Junn E, Lee KW, Jeong BS, et al. Repression of alpha-synuclein immunoreactivity and protein levels in a population-based longitudinal study. J Alzheimers Dis 2010; 20: 293–300.
82. Thome AD, Harms AS, Volpicelli-Daley LA, et al. microRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease. J Neurosci 2016; 36: 2383–2390.
83. Qiu C, Xu W, Winblad B, et al. Vascular risk profiles for dementia and Alzheimer’s disease in very old people: A meta-analysis. J Neurosci Res 2006; 55: 434–441.
84. Ishimaru H, Ueda K, Takahashi A, et al. Changes in presynaptic protein NACP/alpha-synuclein in an ischemic gerbil hippocampus. Brain Res 1998; 788: 311–314.
85. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276: 2045–2047.
86. Hu X, Rea HC, Wiktorowicz JE, et al. Proteomic analysis of hypoxia/ischemia-induced alteration of cortical development and dopamine neurotransmission in neonatal rats. J Proteome Res 2006; 5: 2396–2404.
87. Yoon DK, Hwang IK, Yoo KY, et al. Comparison of alpha-synuclein immunoreactivity and protein levels in ischemic hippocampal CA1 region between adult and aged gerbils and correlation with Cu/Zn-superoxide dismutase. Neurosci Res 2006; 55: 434–441.
88. Golovko MY and Murphy EJ. Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia. Neurosci Lett 2008; 432: 243–247.
89. Joo M and Sadikot RT. PGD synthase and PGD2 in immune responses. Mediators Inflamm 2012; 2012: 503128.
90. Saleem S, Zhuang H, de Brum-Fernandes AJ, et al. PGD1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 2007; 26: 73–78.
91. Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, et al. Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab 2011; 31: 913–923.
92. Kim T, Melita SL, Kaimal B, et al. Poststroke induction of alpha-synuclein mediates ischemic brain damage. J Neurosci 2016; 36: 7055–7065.
93. Dong Z, Ferger B, Paterna JC, et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCre1-1. Proc Natl Acad Sci U S A 2003; 100: 12438–12443.
94. Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, PGC-1alpha. Proc Natl Acad Sci U S A 2000; 97: 13354–13359.
95. Yang Y, Nishimura I, Imai Y, et al. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003; 37: 911–924.
96. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitimates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7: 1144–1150.
97. Lim KL, Chew KC, Tan JM, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation. J Neurosci 2005; 25: 2002–2009.
98. Petrucelli L, O’Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007–1019.
99. Staropoli JF, McDermott C, Martinat C, et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003; 37: 735–749.
100. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 2000; 342: 1560–1567.
101. Torrellas JB, DesJardin LE, MacNeil J, et al. Inactivation of Mycobacterium tuberculosis mannosyltransferase pimB reduces the cell wall lipooligosaccharide and compromises the toxicity associated with mutant alpha-synuclein. J Biol Chem 2003; 278: 20952–20958.
102. Wang C, Ko HS, Thomas B, et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum Mol Genet 2005; 14: 3885–3897.
103. Ko HS, Kim SW, Sriram SR, et al. Identification of far upstream element-binding protein-1 as an authentic Parkinson substrate. J Biol Chem 2006; 281: 16193–16196.
104. Ko HS, von Coelln R, Sriram SR, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. Glycobiology 2009; 19: 743–755.
105. Wang C, Ko HS, Thomas B, et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum Mol Genet 2005; 14: 3885–3897.
109. Gandhi S, Muqit MM, Stanyer L, et al. PINK1 protein in normal human brain and Parkinson’s disease. *Brain* 2006; 129: 1720–1731.

110. Pilsl A and Winklhofer KF. Parkin, PINK1 and mitochondrial integrity: Emerging concepts of mitochondrial dysfunction in Parkinson’s disease. *Acta Neuropathol* 2012; 123: 173–188.

111. Corti O, Lesage S and Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. *Physiol Rev* 2011; 91: 1161–1218.

112. Olivas-Salva M, Macchi F, Coessens V, et al. Alphasynuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. *Neurobiol Aging* 2014; 35: 2625–2636.

113. Liu W, Vives-Bauza C, Acin-Perez R, et al. PINK1 defect causes mitochondrial dysfunction, prostatic defect and alpha-synuclein aggregation in cell culture models of Parkinson’s disease. *PLoS One* 2009; 4: e4597.

114. Todd AM and Staveley BE. Pink1 suppresses alphasynuclein-induced phenotypes in a Drosophila model of Parkinson’s disease. *Genome* 2008; 51: 1040–1046.

115. Pridgeon JW, Olzmann JA, Chin LS, et al. PINK1 protects neurons from ischemic neuronal injury. *Hum Mol Genet* 2015; 24: 4866–4871.

116. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

117. Zhang X, Yan H, Yuan Y, et al. Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease? *Proc Natl Acad Sci U S A* 2002; 99: 15042–15047.

118. Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J Cell Biol* 2010; 189: 211–221.

119. Narendra D, Kane LA, Hauser DN, et al. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. *Autophagy* 2010; 6: 1090–1106.

120. Oliveras-Salva M, Macchi F, Coessens V, et al. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. *Autophagy* 2010; 6: 1090–1106.

121. Matsumoto H, Ito K, Saito Y, et al. DJ-1 has a role in anti-oxidative stress induced putative kinase 1 and dynamin-related protein 1 in transient global ischemia-induced hippocampal neuronal injury. *Biochem Biophys Res Commun* 2015; 460: 397–403.

122. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

123. Zhang X, Yan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

124. Ueda M, Demyanenko S, Fedorenko G, et al. Proline profile and morphological alterations in penumbra after focal phototothmic infarction in the rat cerebral cortex. *Mol Neurobiol.* 2015; 51: 790–799.

125. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

126. Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson’s disease related protein DJ-1: Implications for pathogenesis. *Hum Mol Genet* 2005; 14: 2063–2073.

127. Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson’s disease related protein DJ-1: Implications for pathogenesis. *Hum Mol Genet* 2005; 14: 2063–2073.

128. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

129. Ueda M, Demyanenko S, Fedorenko G, et al. Proline profile and morphological alterations in penumbra after focal phototothmic infarction in the rat cerebral cortex. *Mol Neurobiol.* 2015; 51: 790–799.

130. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

131. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.

132. Zhang X, Yuan H, Yuan Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. *Autophagy* 2013; 9: 1321–1333.
and proteasome inhibition. Biochem Biophys Res Commun 2003; 312: 1342–1348.
141. Hayashi T, Ishimori C, Takahashi-Niki K, et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun 2009; 390: 667–672.
142. Giaime E, Yamaguchi H, Gautier CA, et al. Loss of DJ-1 does not affect mitochondrial respiration but increases ROS production and mitochondrial permeability transition pore opening. PLoS One 2012; 7: e40501.
143. Irrcher I, Aleyasin H, Seifert EL, et al. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 2010; 19: 3734–3746.

Kreibel G, Ruckerbauer S, Burbulla LF, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson’s disease-associated protein DJ-1. PLoS One 2010; 5: e9367.
144. Thomas KJ, McCoy MK, Blackinton J, et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2011; 20: 40–50.
145. Choi J, Sullards MC, Olzmann JA, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 2006; 281: 10816–10824.
146. Bandopadhay Ray, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK in normal human CNS and idiopathic Parkinson’s disease. Brain 2004; 127: 420–430.
147. Blackinton J, Lakshminarasimhan M, Thomas KJ, et al. Formation of a stabilized cysteine sulfonic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem 2009; 284: 6476–6485.
148. Andres-Mateos E, Perier C, Zhang L, et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 2007; 104: 14807–14812.
149. Canet-Aviles RM, Wilson MA, Miller DW, et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004; 101: 9103–9108.
150. Bandopadhyay S and Cookson MR. Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol 2004; 4: 6.
151. Kinumi T, Kimata J, Taira T, et al. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 317: 722–728.
152. Shinbo Y, Niki T, Taira T, et al. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ 2006; 13: 96–108.
153. Fan J, Ren H, Fei E, et al. Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. FEBs Lett 2008; 582: 1151–1156.
154. Ito G, Ariga H, Nakagawa Y, et al. Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1. Biochem Biophys Res Commun 2006; 339: 667–72.
155. Choi MS, Nakamura T, Cho SJ, et al. Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in parkinson’s disease models. J Neurosci 2014; 34: 15123–15131.
156. Duan X, Kelsen SG and Merali S. Proteomic analysis of oxidative stress-responsive proteins in human pneumocytes: Insight into the regulation of DJ-1 expression. J Proteome Res 2008; 7: 4955–4961.
157. Zhou W, Zhu M, Wilson MA, et al. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 2006; 356: 1036–1048.
158. Shendelman S, Jonason A, Martinat C, et al. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004; 2: e362.
159. Zondler L, Miller-Fleming L, Repici M, et al. DJ-1 interactions with alpha-synuclein attenuate aggregation and cellular toxicity in models of Parkinson’s disease. Cell Death Dis 2014; 5: e1350.
160. Chen J, Li L and Chin LS. Parkinson disease protein DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol 2013; 33: 340–359.
161. Shino Y, Taira T, Niki T, et al. DJ-1 restores p53 transcription activity inhibited by Topors/p53BP3. Int J Oncol 2005; 26: 641–648.
162. Im JY, Lee KW, Woo JM, et al. DJ-1 induces thior- doxin 1 expression through the Nrf2 pathway. Hum Mol Genet 2012; 21: 3013–3024.
163. Clements CM, McNally RS, Conti BJ, et al. DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 2006; 103: 15901–15906.
164. Zhong N, Kim CY, Rizzu P, et al. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem 2006; 281: 20940–20948.
165. Mitsugi H, Niki T, Takahashi-Niki K, et al. Identification of the recognition sequence and target proteins for DJ1 protease. FEBS Lett 2013; 587: 2493–2499.
166. Chen J, Li L and Chin LS. Parkinson disease protein DJ-1 converts from azymogen to a protease by carboxyl-terminal cleavage. Hum Mol Genet 2010; 19: 2395–2408.
167. Hao LY, Giasson BI and Bonini NM. DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc Natl Acad Sci U S A 2010; 107: 9474–9452.
168. Girotto S, Cendron L, Bisaglia M, et al. DJ-1 is a copper chaperone acting on SOD1 activation. J Biol Chem 2014; 289: 10887–10899.
169. Kato I, Maita H, Takahashi-Niki K, et al. Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol 2013; 33: 340–359.
170. Zondler L, Miller-Fleming L, Repici M, et al. DJ-1 interactions with alpha-synuclein attenuate aggregation and cellular toxicity in models of Parkinson’s disease. Cell Death Dis 2014; 5: e1350.
172. Kitamura Y, Watanabe S, Taguchi M, et al. Neurontrophic effect of a new DJ-1-binding compound against neurodegeneration in Parkinson’s disease and stroke model rats. Mol Neurodegener 2011; 6: 48.

173. Yu HH, Xu Q, Chen HP, et al. Stable overexpression of DJ-1 protects H9c2 cells against oxidative stress under a hypoxia condition. Cell Biochem Funct 2013; 31: 643–651.

174. Aleyasin H, Rousseaux MW, Phillips M, et al. The Parkinson’s disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci U S A 2007; 104: 18748–18753.

175. Kaneko Y, Tajiri N, Shojo H, et al. Oxygen-glucose-deprived rat primary neural cells exhibit DJ-1 translocation into healthy mitochondria: A potent stroke therapeutic target. CNS Neurosci Ther 2014; 20: 275–281.

176. Kaneko Y, Shojo H, Burns J, et al. DJ-1 ameliorates ischemic cell death in vitro possibly via mitochondrial pathway. Neurobiol Dis 2014; 62: 56–61.

177. Yanagida T, Tsushima J, Kitamura Y, et al. Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury. Oxid Med Cell Longev 2009; 2: 36–42.

178. Meulener MC, Graves CL, Sampathu DM, et al. DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. J Neurochem 2005; 93: 1524–1532.

179. Nural H, He P, Beach T, et al. Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson’s disease patients. Mol Neurodegener 2009; 4: 23.

180. Neumann M, Muller V, Gorner K, et al. Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: Relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol 2004; 107: 489–496.

181. Bretau S, Allen C, Ingham PW, et al. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson’s disease. J Neurochem 2007; 100: 1626–1635.

182. Zhang P, Lei X, Sun Y, et al. Regenerative repair of Pifithrin-alpha in cerebral ischemia via VEGF dependent manner. Sci Rep 2016; 6: 26295.

183. Leker RR, Aharonowiz M, Greig NH, et al. The role of p53-induced apoptosis in cerebral ischemia: Effects of the p53 inhibitor pifithrin alpha. Exp Neurol 2004; 187: 478–486.

184. Cunmsee C, Zhu X, Yu QS, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001; 77: 220–228.

185. Kett LR and Dauer WT. Leucine-rich repeat kinase 2 for beginners: Six key questions. Cold Spring Harb Perspect Med 2012; 2: a009407.

186. Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotyping, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol 2008; 7: 583–590.

187. Daniels V, Vancraenbroeck R, Law BM, Greggio E, Lobbestael E, Gao F, et al. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 2011; 116: 304–315.

188. Lovitt B, Vanderporten EC, Sheng Z, et al. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK). Biochemistry 2010; 49: 3092–3100.

189. Greggio E, Jain S, Kingsbury A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dar-dar. Neurobiol Dis 2006; 23: 329–341.

190. Thaler A, Ash E, Gan-Or Z, et al. The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews. J Neuronal Transm 2009; 116: 1473–1482.

191. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 2006; 354: 422–423.

192. Satake W, Nakabayashi Y, Mizuta I, et al. Genomewide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 2009; 41: 1303–1307.

193. Simon-Sanchez J, Schulte C, Bras JM, et al. Genomewide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 2009; 41: 1308–1312.

194. Li K, Tang BS, Liu ZH, et al. LRRK2 A419V variant is a risk factor for Parkinson’s disease in Asian population. Neurobiol Aging 2015; 36: 2908 e11–e15.

195. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson’s disease. Ann Neurol 2008; 64: 88–92.

196. Farrer MJ, Stone JT, Lin CH, et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia. Parkinsonism Relat Disord 2007; 13: 89–92.

197. Cookson MR, Hardy J and Lewis PA. Genetic neuropathology of Parkinson’s disease. Int J Clin Exp Pathol 2008; 1: 217–231.

198. Rajput A, Dickson DW, Robinson CA, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006; 67: 1506–1508.

199. Kawakami F, Shimada N, Ohta E, et al. Leucine-rich Synuclein and LRRK2 in Tau Phosphorylation. Parkinsons Dis 2015: 734–746.

200. Kawakami F, Yabata T, Ohta E, et al. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 2012; 7: e30834.

201. Avila J, Gomez de Barreda E, Engel T, et al. Tau phosphorylation in hippocampus results in toxic gain-of-function. Biochem Soc Trans 2010; 38: 977–980.

202. Kawakami F and Ichikawa T. The Role of alpha-Synuclein and LRRK2 in Tau Phosphorylation. Parkinsons Dis 2015; 2015: 734–746.

203. Martin L, Page G and Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3beta. Neurochem Int 2011; 59: 235–250.

204. Kawakami F, Suzuki M, Shimada N, et al. Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. FEBS J 2011; 278: 4895–4904.
205. Duka T, Duka V, Joyce JN, et al. Alpha-Synuclein contributes to GSK-3 beta-catalyzed Tau phosphorylation in Parkinson’s disease models. *FASEB J* 2009; 23: 2820–2830.

206. Song B, Ao Q, Wang Z, et al. Phosphorylation of tau protein over time in rats subjected to transient brain ischemia. *Neural Regen Res* 2013; 8: 3173–3182.

207. Wen Y, Yang S, Liu R, et al. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. *Brain Res* 2004; 1022: 30–38.

208. Chen X, Liu Y, Zhu J, et al. GSK-3 beta downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. *Sci Rep* 2016; 6: 20196.

209. Jo C, Gundemir S, Pritchard S, et al. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. *Nat Commun* 2014; 5: 3496.